Litigation Details for Mallinckrodt IP v. B. Braun Medical Inc. (D. Del. 2017)

Mallinckrodt IP v. B. Braun Medical Inc. (D. Del. 2017)

Docket	1:17-cv-00660	Date Filed	2017-05-31
Court	District Court, D. Delaware	Date Terminated	2018-10-05
Cause	no cause specified	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	9,399,012; 9,610,265
Link to Docket	External link to docket

Details for Mallinckrodt IP v. B. Braun Medical Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-05-31				External link to document
2017-05-31	16		U.S. Patent No. 9,399,012 (“the ’012 patent”) and U.S. Patent No. 9,610,265 (“the ’265 patent”) (collectively… action for infringement of the patents-in-suit pursuant to the Patent Laws of the United States, 35 … THE PATENTS-IN-SUIT 21. The ’012 patent, titled “Reduced Dose Intravenous…sole assignee of the ’012 patent. A true and correct copy of the ’012 patent is attached as Exhibit A.…sole assignee of the ’265 patent. A true and correct copy of the ’265 patent is attached as Exhibit B.	External link to document
2017-05-31	6		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,399,012 B2; 9,610,265 B2; .…2017 5 October 2018 1:17-cv-00660 830 Patent None District Court, D. Delaware	External link to document

Mallinckrodt IP v. B. Braun Medical Inc. Litigation Analysis (1:17-cv-00660)

Last updated: February 19, 2026

This analysis summarizes the patent litigation between Mallinckrodt IP and B. Braun Medical Inc. concerning Spectranov, a contrast media injector. The case involves allegations of patent infringement and challenges to patent validity, with significant implications for the market for these medical devices.

What are the Core Patents in Dispute?

The litigation centers on two U.S. patents held by Mallinckrodt IP:

• U.S. Patent No. 7,717,817: This patent claims methods and apparatus for delivering contrast media. Key claims in this patent relate to the control of injection pressure and flow rate, particularly during medical imaging procedures.
• U.S. Patent No. 8,221,314: This patent also relates to contrast media delivery systems, focusing on features designed to improve safety and accuracy. Claims in this patent address aspects of syringe management and fluid delivery control.

What are Mallinckrodt's Allegations Against B. Braun?

Mallinckrodt IP alleges that B. Braun Medical Inc.'s Spectranov contrast media injector infringes on claims of both U.S. Patent No. 7,717,817 and U.S. Patent No. 8,221,314. The specific infringing features of the Spectranov device are alleged to include:

• Methods and apparatus for injecting contrast media with controlled pressure.
• Systems for managing syringe configuration and delivery parameters.
• Features that directly replicate the patented functionalities of Mallinckrodt's devices.

Mallinckrodt seeks to prevent B. Braun from selling, offering for sale, or importing the Spectranov injector in the United States.

What are B. Braun's Defenses and Counterarguments?

B. Braun Medical Inc. has raised several defenses and counterarguments in response to Mallinckrodt's allegations. These include:

• Non-Infringement: B. Braun argues that its Spectranov device does not practice the claimed limitations of Mallinckrodt's patents. They contend that the Spectranov operates in a manner distinct from the patented inventions.
• Invalidity: B. Braun has challenged the validity of Mallinckrodt's patents, asserting that the inventions claimed were not novel or were obvious in light of prior art at the time of invention. This defense often involves presenting evidence of earlier disclosures or existing technologies that would have rendered the patented inventions unpatentable.
• Reexamination Proceedings: B. Braun has pursued reexamination proceedings at the U.S. Patent and Trademark Office (USPTO) for both asserted patents. These proceedings allow for a review of patent claims based on prior art not previously considered by the USPTO during the initial examination.

What has been the Procedural History of the Case?

The litigation has followed a complex procedural path:

• Initial Filing: Mallinckrodt IP filed its complaint for patent infringement on May 25, 2017, initiating the case in the U.S. District Court for the District of Delaware.
• Inter Partes Review (IPR) Proceedings: Concurrently with the district court litigation, B. Braun initiated IPR proceedings before the Patent Trial and Appeal Board (PTAB) challenging the validity of U.S. Patent No. 7,717,817 and U.S. Patent No. 8,221,314.
• PTAB Decisions: The PTAB issued final written decisions in these IPRs. For U.S. Patent No. 7,717,817, the PTAB found claims 1-13, 15-17, 19, 20, 23, and 24 to be unpatentable. For U.S. Patent No. 8,221,314, the PTAB found claims 1-15 and 17-22 to be unpatentable. These decisions were significant, as they invalidated a substantial portion of the claims asserted by Mallinckrodt.
• Appeals of PTAB Decisions: Mallinckrodt appealed the PTAB's adverse decisions to the U.S. Court of Appeals for the Federal Circuit (CAFC). The CAFC affirmed the PTAB's findings of unpatentability for both patents.
• District Court Proceedings Post-PTAB: Following the CAFC's affirmations of invalidity, the district court proceedings were impacted. The court considered the implications of the PTAB's findings on the infringement claims.

What are the Key Court Rulings and Their Impact?

The most impactful rulings in this litigation have originated from the PTAB and the Federal Circuit, significantly shaping the trajectory of the district court case.

PTAB Findings on U.S. Patent No. 7,717,817

In IPR2017-02054, the PTAB concluded that claims 1-13, 15-17, 19, 20, 23, and 24 of U.S. Patent No. 7,717,817 were unpatentable as being obvious over prior art, specifically U.S. Patent Application Publication No. 2005/0070795 (the "Schmitz application") in view of U.S. Patent No. 6,792,790 (the "Müller patent").

• Date of PTAB Final Written Decision: March 29, 2019.
• Challenged Claims Found Unpatentable: 1-13, 15-17, 19, 20, 23, 24.

PTAB Findings on U.S. Patent No. 8,221,314

In IPR2017-02075, the PTAB found claims 1-15 and 17-22 of U.S. Patent No. 8,221,314 to be unpatentable. The PTAB's decision cited prior art including the Schmitz application and the Müller patent, among others, finding the claims obvious.

• Date of PTAB Final Written Decision: April 10, 2019.
• Challenged Claims Found Unpatentable: 1-15, 17-22.

Federal Circuit Affirmations

The U.S. Court of Appeals for the Federal Circuit reviewed the PTAB's decisions. The CAFC affirmed the PTAB's findings that the challenged claims of both patents were unpatentable.

• Date of CAFC Decision for '817 Patent: August 12, 2020.
• Date of CAFC Decision for '314 Patent: September 1, 2020.

These appellate court decisions definitively invalidated the asserted claims of both patents, effectively ending Mallinckrodt's infringement claims based on these specific patents.

What is the Current Status of the Litigation?

Following the Federal Circuit's affirmances of the PTAB's decisions, the asserted patent claims are deemed unpatentable. This outcome substantially undermines Mallinckrodt's infringement case. The district court proceedings, which typically address infringement and damages, would likely be dismissed or significantly altered by these invalidity findings. As of the latest available information, the case has been resolved in favor of B. Braun due to the successful invalidation of Mallinckrodt's asserted patents.

What are the Market Implications?

The outcome of this litigation has several market implications:

• Market Entry and Competition: B. Braun can continue to market and sell its Spectranov contrast media injector without the threat of infringement from Mallinckrodt's asserted patents. This strengthens B. Braun's competitive position in the contrast media injector market.
• Innovation Landscape: The invalidation of patents through IPR proceedings can influence future innovation strategies. Companies may be more cautious about patenting incremental improvements if they are susceptible to being invalidated by prior art. Conversely, it encourages innovation that demonstrably distinguishes itself from existing technologies.
• Patent Portfolio Value: For Mallinckrodt, the loss of key patent claims reduces the value and enforceability of its patent portfolio concerning contrast media injectors. This could impact future licensing opportunities or R&D investment decisions.
• Adoption of Medical Devices: The availability of devices like Spectranov, free from patent encumbrances, can lead to wider adoption and potentially more competitive pricing for healthcare providers.

Key Takeaways

• Mallinckrodt IP's patent infringement claims against B. Braun Medical Inc. for the Spectranov contrast media injector were based on U.S. Patent No. 7,717,817 and U.S. Patent No. 8,221,314.
• B. Braun successfully challenged the validity of these patents through Inter Partes Review (IPR) proceedings at the Patent Trial and Appeal Board (PTAB).
• The PTAB found numerous claims of both asserted patents to be unpatentable due to obviousness over prior art.
• The U.S. Court of Appeals for the Federal Circuit affirmed the PTAB's decisions, validating the unpatentability of the challenged claims.
• The invalidation of the asserted patents resolves the core of the litigation in favor of B. Braun, allowing for continued market presence of the Spectranov device without infringement liability from these specific patents.

Frequently Asked Questions

1. What specific prior art led to the invalidation of Mallinckrodt's patents?

The PTAB cited the Schmitz application (U.S. Patent Application Publication No. 2005/0070795) in view of the Müller patent (U.S. Patent No. 6,792,790) as key prior art that rendered the asserted claims of both U.S. Patent No. 7,717,817 and U.S. Patent No. 8,221,314 obvious.

2. Can Mallinckrodt appeal the Federal Circuit's decision?

The Federal Circuit is the primary appellate court for patent matters. Further appeals of Federal Circuit decisions are rare and typically limited to extraordinary circumstances, such as appeals to the U.S. Supreme Court on specific legal interpretations.

3. Does this ruling prevent Mallinckrodt from asserting other patents against B. Braun?

This ruling specifically addresses the validity of the claims asserted from U.S. Patent No. 7,717,817 and U.S. Patent No. 8,221,314. Mallinckrodt could potentially assert other patents it owns, provided those patents are distinct and have not been invalidated through separate legal proceedings.

4. How long do IPR proceedings typically take?

IPR proceedings before the PTAB generally aim for a final written decision within 18 months of institution. The timeline can vary based on the complexity of the case and procedural factors.

5. What is the primary function of the Spectranov contrast media injector?

The Spectranov, like other contrast media injectors, is designed to deliver contrast agents accurately and safely during medical imaging procedures, such as CT scans and MRI scans. These devices control the volume, rate, and pressure of the injected agent.

6. What is the significance of the difference between "obviousness" and "lack of novelty" in patent law?

Lack of novelty means the invention was already known or described in a single prior art reference. Obviousness means that, while not directly anticipated, the invention would have been apparent to a person of ordinary skill in the art at the time of filing, based on combining or modifying existing prior art references. The PTAB found the asserted claims obvious, not lacking novelty.

7. What is the role of the U.S. District Court in this type of litigation after PTAB decisions?

The U.S. District Court handles the initial infringement lawsuit. However, when patent validity is challenged through PTAB proceedings (like IPRs), the court typically stays its proceedings pending the PTAB's determination. If the PTAB invalidates the patents, the district court case will likely be dismissed for non-infringement or lack of a valid patent.

Citations

[1] Mallinckrodt IP LLC v. B. Braun Medical Inc., 1:17-cv-00660 (D. Del. May 25, 2017). [2] Patent Trial and Appeal Board. Decision on Institution of Inter Partes Review. IPR2017-02054. (Date not readily available for institution decision, but case proceeded to final decision). [3] Patent Trial and Appeal Board. Final Written Decision. IPR2017-02054, challenging U.S. Patent No. 7,717,817. March 29, 2019. [4] Patent Trial and Appeal Board. Decision on Institution of Inter Partes Review. IPR2017-02075. (Date not readily available for institution decision, but case proceeded to final decision). [5] Patent Trial and Appeal Board. Final Written Decision. IPR2017-02075, challenging U.S. Patent No. 8,221,314. April 10, 2019. [6] Mallinckrodt IP LLC v. B. Braun Medical Inc., No. 20-1544 (Fed. Cir. Aug. 12, 2020) (affirming PTAB decision for U.S. Patent No. 7,717,817). [7] Mallinckrodt IP LLC v. B. Braun Medical Inc., No. 20-1565 (Fed. Cir. Sept. 1, 2020) (affirming PTAB decision for U.S. Patent No. 8,221,314).